Renal Resources For You and Your Patients

You work to promote changes in the lives of your patients—but you can't do it without the right tools.

Whether you are looking for educational materials to assist your patients, helpful materials to make your day-to-day job easier, or links to professional journals or renal health organizations—the items listed here can help.

Clinic Corner

An additional level of online support for renal dietitians. The site includes handouts, games, recipes, and more developed specifically for renal dietitians.
A Delicate Balance

An educational program for your patients that discusses what hyperphosphatemia is and how phosphate binders, like FOSRENOL^®, are an available treatment option.
Exclusive Offers

Order tools for you and your staff to use when helping your patients understand the challenges of hyperphosphatemia, including a Kidney Friendly Comfort Foods cookbook and a FOSRENOL^® Patient Pack.
The FOSRENOL^® Focus

Get perspective from other renal dietitians. This interactive program features insights from several different renal dietitians on different aspects of treating CKD Stage 5 and how FOSRENOL^® may be an effective treatment option.
Helpful Links

For further online assistance, review our list of renal health and nutrition Web sites, professional organizations, and clinical journals.
Patient Assistance Program

FOSRENOL^® | at Hand is designed to provide assistance to patients taking FOSRENOL^®.
Community Bulletin Program

A program for your patients to help them make the lifestyle changes of CKD Stage 5 part of their daily routine.

FOSRENOL^® is indicated to reduce serum phosphate in patients with end-stage renal disease.

* Maintenance of reduction was observed for up to 3 years in patients treated with FOSRENOL^®.

Send to a Colleague

Important Safety Information

The most common adverse events were gastrointestinal, such as nausea and vomiting, and generally abated over time with continued dosing
The most common side effects leading to discontinuation in clinical trials were gastrointestinal events (nausea, vomiting, and diarrhea)
Other side effects reported in trials included dialysis graft complications, headache, abdominal pain, and hypotension
Although studies were not designed to detect differences in risk of fracture and mortality, there were no differences demonstrated in patients treated with FOSRENOL^® compared to alternative therapy for up to 3 years
The duration of treatment exposure and time of observation in the clinical program were too short to conclude that FOSRENOL^® does not affect the risk of fracture or mortality beyond 3 years
While lanthanum has been shown to accumulate in the GI tract, liver, and bone in animals, the clinical significance in humans is unknown
Patients with acute peptic ulcer, ulcerative colitis, Crohn's disease, or bowel obstruction were not included in FOSRENOL^® clinical studies. Caution should be used in patients with these conditions
FOSRENOL^® should not be taken by patients who are nursing or pregnant
FOSRENOL^® should not be taken by patients who are under 18 years of age

This site is strictly intended for US residents and is governed solely by US laws and governmental regulations. Please see our online privacy policy for more information.

While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on the site, Shire US Inc. makes no warranties or representations as to its accuracy. Shire US Inc. assumes no liability for any errors or omissions in the content of the site.

FOS1726 1/15/2008